

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement accompanies the new patent application submitted herewith of the following Inventors: Lee Martin GREENBERGER; Frank LOGANZO, Jr.; Carolyn Mary DISCAFANI-MARRO; Arie ZASK; Semiramis AYRAL-KALOUSTIAN;

For: METHOD OF TREATING RESISTANT TUMORS.

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

2. ☐ Previously Cited Information

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120. Prior application is Application Number _____ filed on _____ of _____ for _____.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU673381831US addressed to the Mail Stop DD, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

September 18, 2003
Date

Daniel B. Moran
Daniel B. Moran

3. ☒ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed, except that no copy of a pending U.S. application is enclosed.
4. ☐ Concise Explanation
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or, if readily available, a translation into English of the document is enclosed.
5. Form PTO-1449 is enclosed in duplicate.



Daniel B. Moran

Reg. No. 41,204

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (845) 602-2224

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			Application Number	
			Filing Date	
			First Named Inventor	
			Group Art Unit	
			Lee Martin Greenberger	
			Examiner Name	
Sheet 1 of 2			Attorney Docket Number	
AM101032				

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	US 6,153,590		Andersen, et al.	11-28-2002	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	2.	WO	96/33211		Andersen, Raymond, et al.	10-24-1996		<input type="checkbox"/>
	3.	WO	99/32509		Andersen, Raymond, et al.	08-01-1999		<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
	4.	BESTMANN, VON, H.J., ET AL.; J. Liebig's Ann. Chem., Pgs. 11-17, (1964)	<input type="checkbox"/>	
	5.	COREY, E.J., ET AL.; Tetrahedron Letts., Pgs. 2325-2328, (1967)	<input type="checkbox"/>	
	6.	H. KUNTZEL, ET AL.; Helv. Chim. Acta.; 54, Pg. 868 (1971)	<input type="checkbox"/>	
	7.	PORTULAS, J., ET AL.; Tetrahedron Letts., Pgs. 3617-3618, (1976)	<input type="checkbox"/>	
	8.	Agnew. Chem. Int. Ed. Engl., Pgs. 522-524, (1978)	<input type="checkbox"/>	
	9.	STILL, W.C. AND GENNARI, C.; Tetrahedron Letters, Pg. 4405, (1983)	<input type="checkbox"/>	
	10.	AKIYAMA, S-I, ET AL.; Somatic Cell Mol. Gen., 11, Pgs. 117-126, (1985)	<input type="checkbox"/>	
	11.	SHEN, D-W, ET AL.; J. Biol. Chem., 261, Pgs. 7762-7770, (1986)	<input type="checkbox"/>	
	12.	MCGRATH, T., ET AL.; Biochem. Res. Commun., 145, Pgs. 1171-1176, (1987)	<input type="checkbox"/>	
	13.	LAROCK, RICHARD C., Comprehensive Organic Transformations, VCH Publishers, Pgs. 411-415, (1989)	<input type="checkbox"/>	
	14.	HSLAO, C., ET AL.; Syn Commun., 20, Pgs. 1687-1695, (1990)	<input type="checkbox"/>	
	15.	SKEHAN, P., ET AL.; J. Natl. Cancer Inst., 82(13), Pgs. 1107-1112, (Jul. 4, 1990)	<input type="checkbox"/>	
	16.	GOTTESMAN, M.M., ET AL.; Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells; Plenum Press; Chapter 15; Pgs. 291-301, (1991)	<input type="checkbox"/>	
	17.	GOTTESMAN, M.M., ET AL.; Ann. Rev. Biochem., 62, Pgs. 385-427, (1993)	<input type="checkbox"/>	
	18.	TALPIR, R., ET AL.; Tetrahedron Letters, 35, Pgs. 4453-4456, (1994)	<input type="checkbox"/>	
	19.	GREENBERGER, L.M., ET AL.; Anticancer Drug Resistance, Pgs. 69-106, Norwell, MA: Kluwer Academic Publishers, (1994)	<input type="checkbox"/>	
	20.	ZAMAN, G.J., ET AL.; Proc. Natl. Acad. Sci. USA, 91, Pgs. 8822-8826, (1994)	<input type="checkbox"/>	
	21.	BREUNINGER, L.M., ET AL.; Cancer Res., 55, Pgs. 5342-5347, (1995)	<input type="checkbox"/>	
	22.	ANDERSON, R., ET AL.; Tetrahedron, 51, Pgs. 10653-10662, (1995)	<input type="checkbox"/>	
	23.	ALVAREZ, M., ET AL.; J. Clin. Invest., 95, Pgs. 2205-2214, (1995)	<input type="checkbox"/>	
	24.	ISHIHARA, K., ET AL.; Synlett, Pgs. 721-722, (1995)	<input type="checkbox"/>	
	25.	GREENBERGER, L.M., ET AL.; Oncol. Res., 8, Pgs. 207-218, (1996)	<input type="checkbox"/>	
	26.	GOLDSTEIN, L.J.; European J. Cancer, 32A, Pgs. 1039-1050, (1996)	<input type="checkbox"/>	
	27.	LOE, D.W., ET AL.; European J. Cancer, 32A, Pgs. 945-957, (1996)	<input type="checkbox"/>	
	28.	AUDIA, J.E., ET AL.; J. Med. Chem., 39(14), Pgs. 2773-2780, (1996)	<input type="checkbox"/>	
	29.	KAZMAIER, U.; J. Org. Chem., 61, Pgs. 3694, (1996)	<input type="checkbox"/>	
	30.	KAZMAIER, U., ET AL.; Tetrahedron Letters, 37, Pgs. 7945-7946, (1996)	<input type="checkbox"/>	
	31.	ANDERSON, H.J., ET AL.; Cancer Chemother. Pharmacol. 39, Pgs. 223-226, (1997)	<input type="checkbox"/>	
	32.	ANDERSON, R.J., ET AL.; Tetrahedron Lett., 38, Pgs. 317-320, (1997)	<input type="checkbox"/>	
	33.	TROCK, B.J., ET AL.; J. Natl. Cancer Inst., 89, Pgs. 917-931, (1997)	<input type="checkbox"/>	
	34.	GIANNAKAKOU, P., ET AL.; J. Biol. Chem., 272, Pgs. 17118-17125, (1997)	<input type="checkbox"/>	
	35.	KAVALLARIS, M., ET AL.; J. Clin. Invest., 100, Pgs. 1282-1293, (1997)	<input type="checkbox"/>	
	36.	MEIWES, J., ET AL.; Tetrahedron, asymm, 8, Pgs. 527-536, (1997)	<input type="checkbox"/>	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number		
			Filing Date		
			First Named Inventor		
			Group Art Unit		
			Lee Martin Greenberger		
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	AM101032

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	37.	SPARREBOOM, A., ET AL.; Proc. Natl. Acad. Sci. USA, 94, Pgs. 2031-2035, (1997)		
	38.	BRADSHAW, D.M., ET AL.; J. Clin. Oncol., 16, Pgs. 3674-3690, (1998)		
	39.	MONZO, M., ET AL.; J. Clin. Oncol., 17, Pgs. 1786-1793, (1999)		
	40.	DISCAFANI, C.M., ET AL.; Biochem. Pharmacol., 57, Pgs. 917-925, (1999)		
	41.	RAPP, J., ET AL.; Eur. J. Org. Chem., 10, Pgs. 2609-2622, (1999)		
	42.	DUMONTET, C.; Exp. Opin. Invest. Drugs, 9, Pgs. 779-788, (2000)		
	43.	GIANNAKAKOU, P., ET AL.; Proc. Natl. Acad. Sci. USA, 97, Pgs. 2904-2909, (2000)		
	44.	LITMAN, T., ET AL.; J. Cell Science, 113, Pgs. 2011-2021, (2000)		
	45.	MATSUYAMA, H., ET AL.; J. Org. Chem., 65, Pgs. 4796-4803, (2000)		
	46.	HE, L., ET AL.; Molecular Cancer Therapeutics, 1, Pgs. 3-10, (2001)		
	47.	KELLEY, M.J., ET AL.; J. Natl. Cancer Institute, 93, Pgs. 1886-1888, (2001)		
	48.	BURKART, C.A., ET AL.; Biochim. Biophys. Acta., 1471, Pgs. 01-09, (2001)		
	49.	NICOLETTI, M.I., ET AL.; Clinical Cancer Research, 7, Pgs. 2912-2922, (2001)		
	50.	SALE, S., ET AL.; Mol. Cancer. Thera, 1, Pgs. 215-225, (2002)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.